| 2.48 -0.03 (-1.2%) | 04-19 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.08 | 1-year : | 3.32 |
| Resists | First : | 2.63 | Second : | 2.84 |
| Pivot price | 2.5 |
|||
| Supports | First : | 2.29 | Second : | 1.91 |
| MAs | MA(5) : | 2.47 |
MA(20) : | 2.52 |
| MA(100) : | 5.64 |
MA(250) : | 6.53  |
|
| MACD | MACD : | -0.4 |
Signal : | -0.5 |
| %K %D | K(14,3) : | 37 |
D(3) : | 36.4 |
| RSI | RSI(14): 33.1 |
|||
| 52-week | High : | 13.48 | Low : | 2.25 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ NERV ] has closed above bottom band by 29.9%. Bollinger Bands are 95.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 23 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 2.54 - 2.55 | 2.55 - 2.56 |
| Low: | 2.42 - 2.43 | 2.43 - 2.45 |
| Close: | 2.46 - 2.48 | 2.48 - 2.5 |
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of schizophrenia; and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
Tue, 02 Apr 2024
Do Options Traders Know Something About Minerva Neurosciences (NERV) Stock We Don't? - Yahoo Movies UK
Tue, 27 Feb 2024
Analyst Rating: Will Minerva Neurosciences Inc (NERV) Stock Do Better Than the Market? - InvestorsObserver
Tue, 27 Feb 2024
Minerva stock falls as FDA rejects schizophrenia drug - Seeking Alpha
Tue, 27 Feb 2024
Minerva Neurosciences Receives Complete Response Letter from FDA for New Drug Application for Roluperidone for ... - Yahoo Finance
Thu, 22 Feb 2024
Minerva Neurosciences: Q4 Earnings Snapshot - Quartz
Thu, 22 Feb 2024
Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Business Updates - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 7 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 22.2 (%) |
| Held by Institutions | 35 (%) |
| Shares Short | 40 (K) |
| Shares Short P.Month | 122 (K) |
| EPS | -4.62 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -4.08 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -25.9 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -3.31 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -15 (M) |
| Levered Free Cash Flow | -13 (M) |
| PE Ratio | -0.54 |
| PEG Ratio | 0 |
| Price to Book value | -0.61 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.18 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|